benlysta news
Your Search Returned 50 tagged news reports
Biogen sells royalty rights on lupus drug to Canadian fund
Bangalore :: India | 9 months ago
Credibility
Biotechnology company Biogen Idec sold its royalty rights on the lupus treatment Benlysta to Canadian investment firm DRI Capital Inc in exchange for a multiple of the royalty amount it was due to receive over three years. Human Genome Sciences and
Tags:
Lower Price of Benlysta Could Boost HGSI
London :: United Kingdom | 12 months ago
Credibility
Jordo is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. SLE) treatment. The company has made it abundantly clear that it is open to purchase offers. Tom Watkins,
Tags:
Investing in Biotech Stocks: The Latest Buyout Candidate
London :: United Kingdom | 1 year ago
Credibility
The biotechnology buyout binge continued this week, driving profits for those investing in biotech stocks ...Human Genome argued the unsolicited bid did not reflect the company's inherent value. GSK adamantly insisted its bid, an 81% premium when
Tags:
Human Genome Lays Out Its Valuation Case
Alexandria :: VA :: USA | 1 year ago
Credibility
last week, management figured it would be a good venue to state its case. It's not often you hear a CEO on an earnings call say, "We do not plan to take you through the financial results in today's call." What's really interesting is that I don't
Tags:
Human Genome exploring options after rebuff of Glaxo
New York City :: NY :: USA | 1 year ago
Credibility
Content Signage is pictured on the company Human Genome said it would not comment on the process, but reiterated that Glaxo 's $13 per share offer was not sufficient and failed to account for the inherent value of the company's pharmaceutical assets.
Tags:
For Sale, Just Not at That Price
Alexandria :: VA :: USA | 1 year ago
Credibility
Human Genome Sciences is partnered with Glaxo on their lupus drug Benlysta and has licensed a few other drugs to the pharma giant. The $13-per-share offer was flat-out rejected by Human Genome Sciences' board, but the board figured it should see if
Tags:
Keryx: A Biotech For Aggressive Investors
Alexandria :: VA :: USA | 1 year ago
Credibility
Currently, its main focus is on drugs that treat renal disease and cancer. It has two drugs in phase 3 trials : Zerenex (ferric citrate), which is an oral, iron-based compound used to treat patients with end-stage renal disease, and KRX-0401 (
Tags:
3 Stocks to Get on Your Watchlist
Mumbai :: India | 1 year ago
Credibility
Stocks to Get on Your Watchlist Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist,
Tags:
Being Selective in Biotech: Carol Werther
Boston :: MA :: USA | 1 year ago
Credibility
Articles In an industry steeped in complex research and speculative drug development, successful biotech investing requires real sophistication. Senior Biotechnology Analyst Carol Werther of Boston-based Summer Street Research Partners brings her
Tags:
Biotech Stocks: Biotech analysts don’t see HGS takeover on horizon
New York City :: NY :: USA | over 1 year ago
Credibility
A key obstacle, they said, is HGS's sinking stock price, which slid below $10 a share to close at $9.88 on Wednesday after the biotech group reported weaker-than-expected quarterly sales for its new lupus drug Benlysta. The drug, the first to be
Tags:
